Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study.
Troels ThimLars JakobsenRebekka Vibjerg JensenNicolaj StøttrupAshkan EftekhariErik Lerkevang GroveSanne Bøjet LarsenJacob Thorsted SørensenSteen CarstensenSahar AmiriKarsten Tange VeienEvald Høj ChristiansenChristian Juhl TerkelsenMichael MaengSteen Dalby KristensenPublished in: Cardiology research and practice (2023)
= 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.
Keyphrases
- percutaneous coronary intervention
- liver failure
- respiratory failure
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- patients undergoing
- coronary artery disease
- acute myocardial infarction
- drug induced
- aortic dissection
- antiplatelet therapy
- atrial fibrillation
- coronary artery bypass grafting
- early stage
- hepatitis b virus
- intensive care unit
- mechanical ventilation
- extracorporeal membrane oxygenation
- human health